Medpage Today on MSN1d
Tirzepatide Officially Puts GLP-1 Meds on the Map for Obesity-Related Heart Failure
CHICAGO -- A long-acting GIP/GLP-1 receptor agonist conferred significant clinical benefit for people with obesity and ...
Study supports evidence that GLP-1 meds help curb alcohol abuse
A new study supports the notion that the same mechanisms that help folks lose weight with Ozempic and its kin also work to ...
Medpage Today on MSN4d
GLP-1 Drugs Could Help People With Alcohol Use Disorder
Some GLP-1 receptor agonists may hold promise as treatments for alcohol use disorder (AUD), a Swedish observational study ...
News Medical on MSN2h
GLP-1 drugs, like semaglutide, lower risk of hospitalizations for alcohol use disorder
Findings suggest semaglutide and other GLP-1 agonists may significantly reduce alcohol use disorder hospitalizations, ...
'Staggeringly high' discontinuation rates for GLP-1 drugs like Ozempic or Wegovy
The use of diabetes and weight-loss medications like Ozempic or Wegovy—called GLP-1 drugs—has exploded in recent years, with ...
More Evidence That GLP-1 Meds Curb Alcohol Abuse
The diabetes meds in question are called GLP-1 RAs (sometimes abbreviated as GLP-1s). They include diabetes meds like ...
Exenatide, a GLP-1 analog, by IV during cardiac surgery did not reduce organ injury or death
A large-scale clinical trial found that intravenous infusion of exenatide, a glucagon-like peptide-1 (GLP-1) analog ...
Benefits Pro2h
Pharmacies lobby FDA for right to keep making weight-loss drugs
Pharmacies that make customized medications are asking the federal Food and Drug Administration to protect their right to ...
Renal & Urology News2h
AHA: GLP-1 RA, SGLT-2i Use Can Lower Risk for MI, Recurrent Stroke in Stroke Survivors
Mohammad Ali Sheffeh, MD, from the Mayo Clinic in Rochester, Minnesota, and colleagues examined the efficacy of GLP-1 RA or SGLT-2i initiation for reducing mortality or cardiovascular events among ...
AHA 2024: GLP-1R agonist associated with better clinical outcomes in heart failure and CKD
Real-world data on GLP-1R agonists’ safety in heart failure and CKD patients was investigated using the TriNetX Research ...
Medicaid fuels US coverage of Novo, Lilly weight-loss drugs
U.S. government health plans account for the lion's share of coverage for popular new weight-loss drugs, far beyond the ...
Diabetes and weight loss drugs shown to reduce alcohol-related hospitalizations, study finds
Ozempic, Wegovy and other GLP-1 drugs have been shown to curb alcoholism, a new study suggests. Researchers explain why ...